By Ryan Scott June 1, 2024
A lower risk of disease recurrence was seen when combining anthracycline and chemotherapy to treat certain patients with breast cancer.
Anthracycline plus a taxane and cyclophosphamide was linked to a lower risk of recurrence at 3 years in patients with MammaPrint (MP) high-2–risk, BluePrint Luminal B, hormone receptor (HR)–positive, HER2-negative early breast cancer, according to data from the FLEX registry trial (NCT03053193).
Findings showed that patients with Luminal MP high-1–risk disease had comparable 3-year recurrence-free survival (RFS) rates when treated with a taxane and cyclophosphamide (n = 346) at 97.1% (95% CI, 95.1%-99.2%) and with anthracycline plus a taxane and cyclophosphamide (n = 184) at 95.3% (95% CI, 91.8%-98.8%). However, patients with Luminal MP high-2–risk disease had a worse 3-year RFS rate when treated with the 2-drug regimen (n = 40) at 86.4% (95% CI, 74.2%-100%) compared with the anthracycline regimen (n =44) at 97.7% (95% CI, 93.4%-100%).
“In the real-world FLEX registry trial, patients with MammaPrint high-2–risk, BluePrint Luminal B, HR-positive, HER2-negative early breast cancer had a higher 3-year RFS rate with anthracycline plus a taxane and cyclophosphamide than with a taxane and cyclophosphamide therapy in this non-randomized cohort,” Joyce O’Shaughnessy, MD, explained in a presentation of the data at the presented at the 2024 ASCO Annual Meeting. “Luminal MammaPrint high-1–risk patients had similar 3-year RFS rates with an adjuvant a taxane and cyclophosphamide [compared] with anthracycline plus a taxane and cyclophosphamide.”
Link to article here.
